News & Press
Motif Neurotech Selected for ARPA-H's $139M EVIDENT Behavioral Health Initiative
ARPA-H4/21/2026·04/21/26🌐 USA
Summary
Motif Neurotech was named among the first research teams in ARPA-H's $139 million EVIDENT program, a federal initiative supporting more precise, measurable behavioral health treatments. Motif will use the funding to collect additional adjunctive data alongside its RESONATE depression trial to help identify which patients respond best to neuromodulation.
Why it matters
Federal validation and non-dilutive funding alongside Motif's ongoing FDA clinical trial strengthens its path toward a data-backed therapeutic BCI for depression.
#BCI
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trialAlready a member? Sign in